There is no measured KLOW peptide before and after. Four compounds share the vial, no study has given them together, and two of the four have never been given to a person in a published trial.
KLOW is 80 mg of four compounds: GHK-Cu, BPC-157, TB-500 and KPV. Studies of the combination number zero. The nearest human data belongs to BPC-157, and it is a phone survey of 16 knee patients. TB-500 and KPV have no published human trial of any kind. GHK-Cu’s controlled evidence is topical.
What has been measured, ingredient by ingredient
There is no result for KLOW, so the honest version of this page is a per-ingredient audit. Here is every human number that exists in the vial.
| Component | mg | Human result on record |
|---|---|---|
| GHK-Cu | 50 mg | Controlled dermal studies, topical application only |
| BPC-157 | 10 mg | A phone survey of 16 knee patients, uncontrolled |
| TB-500 | 10 mg | None published |
| KPV | 10 mg | None published |
Read down the third column. Two rows are empty, one is a route this vial does not use, and one is a phone survey. That is the evidence base a KLOW photograph is standing on:
- GHK-Cu — real controlled evidence, generated by rubbing it on skin rather than injecting it.
- BPC-157 — one uncontrolled retrospective review, outcome collected by telephone.
- TB-500 and KPV — nothing published in humans, for any indication.
That table is the whole human record. Everything else attributed to KLOW is a rodent study, a mechanism, or a photograph. The KLOW complete guide covers what is in the vial.
The BPC-157 number, and what it is
Almost every recovery claim on a KLOW page traces to one 2021 retrospective chart review. A single Florida clinic looked back at 17 patients given BPC-157 injections into the knee. 16 were reachable by phone at six to twelve months. 14 said they felt better.
No control arm, no validated outcome measure, no imaging, and the clinic surveyed its own patients. The placebo response in knee studies runs 30–60%, which is the band that result has to be read against.
Despite the robust preclinical findings, human data are extremely limited, no large-scale randomized trials exist, and BPC-157 should be considered investigational pending well-designed clinical trials.
McGuire et al., Current Reviews in Musculoskeletal Medicine, 2025We work through the design in the knee case series, and the same borrowing problem applies to the three-compound blend in GLOW before and after.
KPV is the newest ingredient and the emptiest record
KPV is the one thing KLOW has that GLOW does not. Its evidence is narrow, clean, and entirely preclinical.
KPV showed significant anti-inflammatory effects in 2 murine models of colitis.
Kannengiesser et al., Inflammatory Bowel Diseases, 2008Two 2008 papers, both mice, one showing PepT1-mediated uptake at nanomolar concentrations in culture. Nothing has followed in humans, for colitis or anything else. So the ingredient that distinguishes KLOW contributes exactly nothing to a before-and-after. See the KPV colitis research.
KLOW Blend
The four-component blend described here, co-lyophilized in one vial, with a third-party certificate of analysis matched to the lot.
Why a four-compound photo tells you even less
A before-and-after is an attribution claim: this changed because of that. A blend of four makes the claim unresolvable by construction.
- Four simultaneous variables. If something changed, four things changed, plus whatever else the person changed alongside it.
- The ratio is fixed. Nothing can be varied to test which ingredient matters, because they are in one cake.
- The blue is copper, not a result. GHK-Cu is 62.5% of the mass, and copper(II) is blue in solution.
- Most photos are skin. Those borrow GHK-Cu’s topical evidence for an injected vial — see injectable vs topical.
The copper load is worth its own look for anyone reading results pages as a reason to run a vial faster: about 7.9 mg of elemental copper against a 10 mg adult daily upper intake level. See KLOW side effects and KLOW dosage.
What a real before-and-after looks like
For calibration, a peptide with a genuine measured result is tesamorelin: visceral fat down 15.2% on CT over 26 weeks, against a 5.0% gain on placebo, in 412 randomized adults.
Notice what that has and a KLOW photo does not. A scan. A comparison group. A number that can be wrong. That is the standard, and it is reachable, which is why its absence here is worth naming rather than working around.
What the vial can be checked on is its contents rather than its effects. KLOW benefits traces each claim to its ingredient, and where to buy KLOW covers the four checks a blend certificate has to survive.
KLOW Blend
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- No result has been measured for KLOW. Studies of the four-compound combination number zero in any species.
- TB-500 and KPV have no published human trial, so half the vial contributes nothing to any before-and-after.
- The BPC-157 number everyone quotes is a phone survey: 16 knee patients reached, 14 reporting relief, no controls.
- Skin photos borrow GHK-Cu's topical evidence for an injected vial. Injected GHK-Cu has no randomized trial.
- With four fixed-ratio variables, no observed change can be attributed to any one ingredient.
What we're watching
The first thing that would put a real number on this page is the obvious unrun experiment: the blend against each constituent alone, one endpoint, one species. Second would be the first human KPV trial, which would move the newest ingredient from mechanism to outcome. Third, and most consequential by mass, a randomized trial of injected GHK-Cu. Until one of those lands, every KLOW before-and-after is a photograph of a person who changed four things at once.
Frequently asked questions
Are there real KLOW peptide before and after results?
Not measured ones. No study has administered the four compounds together in any species, so there is no published result for the blend. The images in circulation are personal photographs with no baseline, no control and no record of what else changed.
How long does KLOW take to work?
No study defines a timeline, because no study has given the blend. Two of its four ingredients have no published human dose to reconstruct one from.
What is the strongest human evidence behind KLOW?
A 2021 retrospective chart review of 17 knee patients given BPC-157, not KLOW. Sixteen were reached by phone at six to twelve months and fourteen reported relief. There was no control arm and no validated outcome measure.
Does KPV have any human results?
No. KPV's record is two 2008 papers in murine colitis models, one showing uptake through the PepT1 transporter at nanomolar concentrations in culture. No human trial has been published.
Does the blue color mean it is working?
No. The blue is copper(II) from GHK-Cu, which is 62.5% of the vial by mass. It confirms copper is present and says nothing about purity, ratio or effect.
References
- Lee, E., & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27(4), 8–13. PMID 34324435
- Vasireddi, N., Hahamyan, H., Salata, M. J., et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal, 21(4). https://doi.org/10.1177/15563316251355551
- McGuire, F. P., Martinez, R., Lenz, A., Skinner, L., & Cushman, D. M. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 18(12), 611–619. https://doi.org/10.1007/s12178-025-09990-7
- Kannengiesser, K., Maaser, C., Heidemann, J., et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 14(3), 324–331. https://doi.org/10.1002/ibd.20334
- Dalmasso, G., Charrier-Hisamuddin, L., Nguyen, H. T., et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1), 166–178. https://doi.org/10.1053/j.gastro.2007.10.026
- Sun, J., Xue, P., Liu, J., et al. (2021). Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS Biomaterials Science & Engineering, 7(10), 4859–4869. https://doi.org/10.1021/acsbiomaterials.1c00792
- Dou, Y., Lee, A., Zhu, L., et al. (2020). The potential of GHK as an anti-aging peptide. Aging Pathobiology and Therapeutics, 2(1), 58–61. https://doi.org/10.31491/apt.2020.03.014
- Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987. https://doi.org/10.3390/ijms19071987
- Dymek, M., Warszyński, P., & Sikora, E. (2023). GHK Peptide Permeability and Its Effects in Anti-Aging Skincare Topical Formulations. Pharmaceutics, 15(10), 2485. https://doi.org/10.3390/pharmaceutics15102485
- Ying, Y., Lin, C., Tao, N., et al. (2023). Thymosin β4 and actin: Binding modes, biological functions and clinical applications. Current Protein and Peptide Science, 24(1), 78–88. https://doi.org/10.2174/1389203724666221201093500
- Xing, Y., Ye, Y., Zuo, H., & Li, Y. (2021). Progress on the Function and Application of Thymosin β4. Frontiers in Endocrinology, 12, 767785. https://doi.org/10.3389/fendo.2021.767785